POTENTIAL EFFICACY OF LOMITAPIDE, A MTP (MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN) INHIBITOR, ON SURVIVAL IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOFH): RESULTS OF AN EVENT MODELLING ANALYSIS

被引：0
|
作者：
Leipold, R. [1 ]
Raal, F. [2 ]
Ishak, J. [1 ]
Phillips, H. [3 ]
Deanfield, J. [4 ]
机构：
[1] Evidera, Bethesda, MD USA
[2] Univ Witwatersrand, Johannesburg, South Africa
[3] Aeger Pharmaceut Ltd, Reading, Berks, England
[4] UCL, London, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.159
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM93
引用
收藏
页码：A373 / A374
页数：2
相关论文
共 15 条
  • [1] Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia
    Kolovou, Genovefa
    Diakoumakou, Olga
    Kolovou, Vana
    Fountas, Epameinondas
    Stratakis, Stavros
    Zacharis, Evangelos
    Liberopoulos, Evangelos N.
    Matsouka, Fedra
    Tsoutsinos, Alexandros
    Mastorakou, Irene
    Katsikas, Theodoros
    Mavrogeni, Sophie
    Hatzigeorgiou, Georgios
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (02) : 157 - 165
  • [2] ACHIEVEMENT OF EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) TARGETS WITH LOMITAPIDE, A MICROSOMAL TRANSFER PROTEIN INHIBITOR IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOFH)
    Phillips, H.
    Ager, M.
    Hutchings, A.
    ATHEROSCLEROSIS, 2016, 252 : E33 - E33
  • [3] Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
    Claudia Stefanutti
    Current Atherosclerosis Reports, 2020, 22
  • [4] PHASE 3 STUDY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR (MTP-I) LOMITAPIDE IN SUBJECTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): 56-WEEK RESULTS
    Cuchel, M.
    Meagher, E.
    Marais, A. D.
    Blom, D. J.
    Theron, H. du Toit
    Shah, P. K.
    Hegele, R. A.
    Bloeden, L. T.
    Sasiela, W. J.
    Rader, D. J.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 14 - 14
  • [5] A phase 3 study of the microsomal triglyceride transfer protein (MTP) inhibitor lomitapide in patients with homozygous familial hypercholesterolemia
    Cuchel, M.
    EUROPEAN HEART JOURNAL, 2012, 33 : 951 - 951
  • [6] Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
    Stefanutti, Claudia
    CURRENT ATHEROSCLEROSIS REPORTS, 2020, 22 (08)
  • [7] Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolemia phenotype
    Fountas, E.
    Diakoumakou, O.
    Kolovou, V.
    Stratakis, S.
    Zacharis, E.
    Liberopoulos, E.
    Matsouka, F.
    Tsoutsinos, A.
    Mastorakou, I.
    Katsikas, T.
    Mavrogeni, S.
    Hatzigeorgiou, G.
    Kolovou, G.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3258 - 3258
  • [8] Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
    Blom, Dirk J.
    Averna, Maurizio R.
    Meagher, Emma A.
    Theron, Hendrik du Toit
    Sirtori, Cesare R.
    Hegele, Robert A.
    Shah, Prediman K.
    Gaudet, Daniel
    Stefanutti, Claudia
    Vigna, Giovanni B.
    Larrey, Dominique
    Bloedon, LeAnne T.
    Foulds, Pamela
    Rader, Daniel J.
    Cuchel, Marina
    CIRCULATION, 2017, 136 (03) : 332 - 335
  • [9] Apheresis Treatment does not Affect the Lipid-Lowering Efficacy of Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia
    Cuchel, Marina
    Meagher, Emma A.
    Theron, H. du Toit
    Blom, Dirk
    Marais, A. D.
    Hegele, Robert A.
    Averna, Maurizio
    Sirtori, Cesare
    Shah, Prediman K.
    Gaudet, Daniel
    Stefanutti, Claudia
    Vigna, Giovanni B.
    du Plessis, A. M. E.
    Bloedon, LeAnne T.
    Rader, Daniel J.
    CIRCULATION, 2012, 126 (21)
  • [10] Reducing low density lipoprotein cholesterol (LDL-C) in homozygous familial hypercholesterolemia (HoFH) with a microsomal triglyceride transfer protein (MTP) inhibitor may reduce CV events
    Ager, M. L.
    Hutchings, A.
    Phillips, H.
    EUROPEAN HEART JOURNAL, 2016, 37 : 8 - 9
12